| Objective:More plus docetaxel chemotherapy with doxorubicin, cyclophosphamide, programs recurrence of breast cancerpatients with metastasis and disease-free survival time of impact. To further explore the improvement of the survival advantage of docetaxel.Materials and Methods:Selected243cases with primary unilateral breast cancer patients attending breast in the Second Hospital of Shanxi Medical Branch in January2005to February2009, all patients had Modified Radical postoperative chemotherapy for the first time and a definite pathological diagnosis and TNM stage. Using the method of test, t test and analysis of variance, analysis of its clinical and pathological features and chemotherapy and the recurrence rate and disease-free survival time.Result:1. Two groups of patients with recurrence rate and disease-free survival timeTwo groups a total of43patients with recurrence and metastasis, Total of recurrence and metastasis rate was17.7%(43/243), which the TAC or AC'T in patients treated with recur-rence and metastasis rate was10.8%(13/120), there were significant differences (χ2=7.665, P=0.006<0.05). The two groups of patients, the average disease-free survival time for1,154days and1,035days, no significant difference between(t=-1.925, p=0.055>0.05).2. Clinicopathological characteristics and recurrence rate and disease-free survival time(1) Menstruation:Sick before and after menopause occurred in25cases and19cases of recurrence and metastasis, the total recurrence rates were20.0%(25/125) and16.10%(19/118), which the TAC or AC'T treatment group before and after menopause ill recurrence rates were12.90%(8/62) and8.62%(5/58), AC treatment group before and after menopause in patients with recurrence and metastasis rates were26.98%(17/63) and23.33%(14/60), obtained after χ2testing, menopause recurrence rate was no significant difference, however, two groups of premenopausal and postmenopausal patients recurrence rate differences were statistically significant(χ2=3.872, P=0.049<0.05;χ2=4.726, P=0.030<0.05). Two groups of patients the average disease-free survival in premenopausal1,258days and1,137days respectively, the average disease-free sur-vival of postmenopausal1,308days and1,229days respectively, patients with disease-free survival showed no significant difference(t=-1.854, p=0.065>0.05; t=-1.846,p=0.066>0.05).(2) Lymph node:Lymph node-positive and-negative patients were25cases and18cases of recurrence and metastasis, the total recurrence rate is17.61%(25/142) and17.82%(18/101), which the TAC or AC'T treatment group of node-positive and-negative patients recurrence rates were11.11%(8/72) and10.42%(5/48), AC treatment group of node-positive and node-negative patients with recurrence and metastasis rates were24.29%(17/70) and24.53%(13/53), obtained after χ2testing, node-positive and negative lymph node recurrence rate betw-een patients and two lymph node-negative patients with recurrence and metastasis rates were no significant difference, but two sets of node-positive patients with recurrence rate difference was statistically significant(χ2=4.247, P=0.039<0.05). Two sets of node-positive patients, the aver-age disease-free survival time were1,409days and1,293days respectively, lymph node-negative patients, the average disease-free survival time were1,401days andl,309days respec-tively, two groups of lymph node-positive patients and two lymph node-negative patients with disease-free survival showed no significant difference(t=-1.923, p=0.056>0.05; t=-1.894, p=0.059>0.05).(3) Estuarial Receptor(ER):ER-positive and ER-negative patients were26cases and17cases of recurrence and metastasis, the total recurrence rate is16.15%(26/161) and20.73%(17/82), which the TAC or AC'>T treatment of ER-positive and ER-negative patients recur-rence rates were11.25%(9/80) and10.00%(4/40) respectively, AC treatment of ER-positive and ER-negative patients recurrence rates were20.99%(17/81)and30.95%(13/42), upon χ2examination obtained, ER-positive and negative total recurrence rate between patients and two groups of ER-positive patients between relapse metastasis rate was no significant difference, however, the recurrence rate of ER-negative patients with a significant difference(χ2=5.473, P=0.019<0.05). The average of two groups of patients with ER-positive disease-free survival time for1,295days and1,198days, the average of two groups of patients with ER-negative disease-free survival time was1,352days and1,085days, two groups of ER-positive patients and two groups of patients with ER-negativedisease-free survival time differences were not statistically significant(t=-1.931, p=0.055>0.05; t=-1.900, p=0.059>0.05).(4)TNM:TAC or AC'T treatment group phase II、IIA and IIB patients with recurrence and metastasis rates were8.54%、7.50%and9.52%, AC treatment group phase II、 IIA and ⅡB patients with recurrence and metastasis rateswere17.98%、20.00%and18.18%, two sets of sub-period the recurrence rate showed no significant difference. TNMIIIA breast cancer patients a total of20cases of recurrence and metastasis, total of recurrence and metastasis rate was27.78%(20/72), which the TAC or AC'T treatment group of38patients,6cases of recurrence andmetastasis, the transfer rate is15.79%, AC treatment group of34patients14cases of recurrence and metastasis, the transfer rate is41.18%, there was significant difference between the two groups(χ2=5.765, P=0.016<0.05). TAC or AC'T treatment group phase Ⅱ、 IIA and Category IIB period and the average inpatients with stage IIIA disease-free survival time were1,341、1,395、1,342and1,190days, the average disease-free survival time of patients in the AC treatment group were1,253、1,209、1,153and1,087days, between the two groups stage disease-free survival time differences were notstatistically significant.3. Different medication in patients with recurrence rate and disease-free survival timePlus docetaxel adjuvant chemotherapy in breast cancer patients, the TAC of patients with recurrent metastasis rate was18.0%, AC'T in patients with recurrence and metastasis rate of5.71%, AC in patients with recurrence and metastasis rate was24.39%, upon χ2examination obtained, Statistically significant difference between the three groups in general(χ2=10.688, p=0.005<0.05). After pairwise comparisons, there is a difference of statistically with AC'T and AC, Others are not statistically significant. AC、TAC and AC'T in patients with average disease-free survival time for1,035、1,267and1,142days, After analysis of variance, no significant differences between the groups.Conclusion:1. Adjuvant chemotherapy with docetaxel (T) can reduce the risk of recurrence of breast cancer patients in the AC program; there is no effect on the disease-free survival time.2. Whether postmenopausal, node-positive, ER-receptor negative, TNM stage for patients with stage IIIA plus adjuvant chemotherapy with docetaxel (T) could reduce the recurrence transfer rate, but little impact of disease-free survival time. Prompt clinical and pathological features of patients and have a certain relationship tothe efficacy of docetaxel.3. The docetaxel medication in different ways will show a different efficacy, AC'T and TAC reduce the recurrence rate of breast cancer patients, but no significant difference between the different drugs the way. |
PDF Full Text Request